Tags

Type your tag names separated by a space and hit enter

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
Neurology. 2005 Apr 12; 64(7):1294-7.Neur

Abstract

Baseline CSF amyloid beta-peptide-42 (Abeta42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of Abeta42 and P-tau.

Authors+Show Affiliations

Department of Neurology,University of Kuopio, Finland. .No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15824371

Citation

Herukka, Sanna-Kaisa, et al. "CSF Abeta42 and Tau or Phosphorylated Tau and Prediction of Progressive Mild Cognitive Impairment." Neurology, vol. 64, no. 7, 2005, pp. 1294-7.
Herukka SK, Hallikainen M, Soininen H, et al. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64(7):1294-7.
Herukka, S. K., Hallikainen, M., Soininen, H., & Pirttilä, T. (2005). CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology, 64(7), 1294-7.
Herukka SK, et al. CSF Abeta42 and Tau or Phosphorylated Tau and Prediction of Progressive Mild Cognitive Impairment. Neurology. 2005 Apr 12;64(7):1294-7. PubMed PMID: 15824371.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. AU - Herukka,Sanna-Kaisa, AU - Hallikainen,Merja, AU - Soininen,Hilkka, AU - Pirttilä,Tuula, PY - 2005/4/13/pubmed PY - 2006/2/14/medline PY - 2005/4/13/entrez SP - 1294 EP - 7 JF - Neurology JO - Neurology VL - 64 IS - 7 N2 - Baseline CSF amyloid beta-peptide-42 (Abeta42), tau, and phosphorylated tau (P-tau) levels from 46 control subjects and 78 patients with mild cognitive impairment (MCI) were measured. Twenty-three patients with MCI developed dementia during the study. Abnormal biomarkers were found early in the course of Alzheimer disease (AD). The most predictive assay for AD among the patients with MCI was the combination of Abeta42 and P-tau. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/15824371/CSF_Abeta42_and_tau_or_phosphorylated_tau_and_prediction_of_progressive_mild_cognitive_impairment_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=15824371 DB - PRIME DP - Unbound Medicine ER -